Mizuho Bullish on Neumora's Lead Drug Prospects, Initiates Neumora at Outperform Rating
Monday, 8 July 2024, 17:38
Mizuho Initiates Coverage of Neumora Therapeutics
Rating and Potential Upside
Mizuho has started covering Neumora Therapeutics with an outperform rating, anticipating over 50% upside potential for the stock if Phase 3 data for navacaprant is favorable.
The bullish outlook underscores the positive prospects for Neumora and its lead drug, suggesting a promising investment opportunity for interested investors.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.